Aligos Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Nuechterlein Carole | — | Purchase | 7,933,601 | $0.76 | $6,029,537 | 11,025,941 | Oct 25, 2023 |
| BLATT LAWRENCE | Chief Executive Officer | Award / Grant | 610,277 | $0.76 | $463,811 | 1,847,575 | Oct 25, 2023 |
| Scopa James Paul | — | Award / Grant | 183,083 | $0.76 | $139,143 | 183,083 | Oct 25, 2023 |
| Woiwode Thomas | — | Other | 8,383 | — | — | 8,383 | Jun 11, 2021 |
| Woiwode Thomas | — | Other | 485,979 | — | — | 1,943,916 | Apr 26, 2021 |
| Beigelman Leonid | President | C | 1,437 | — | — | 18,355 | Oct 20, 2020 |
| BLATT LAWRENCE | Chief Executive Officer | C | 41,016 | — | — | 41,016 | Oct 20, 2020 |
| Nuechterlein Carole | — | C | 662,799 | — | — | 2,808,790 | Oct 20, 2020 |
| Quan Lucinda Y. | See Remarks | C | 1,697 | — | — | 8,532 | Oct 20, 2020 |
| Symons Julian A. | See Remarks | C | 1,452 | — | — | 394,064 | Oct 20, 2020 |
| Versant Venture Capital VI, L.P. | — | C | 198,839 | — | — | 2,344,830 | Oct 20, 2020 |
| Vivo Capital Surplus Fund VIII, L.P. | — | C | 260,380 | — | — | 260,380 | Oct 20, 2020 |
| Woiwode Thomas | — | C | 198,485 | — | — | 662,444 | Oct 20, 2020 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | — | C | 1,335,048 | — | — | 1,335,048 | Oct 20, 2020 |
| Novo Holdings A/S | — | Purchase | 200,000 | $15.00 | $3,000,000 | 2,614,563 | Oct 20, 2020 |